Indian Clinical Trials Market Outlook to 2025 - Phase I Trials Projected to Witness a Remarkable CAGR of 10.5%, Attributed to Increasing R&D Spending by Pharma & Biopharma Companies - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Mar 13, 2019--The “Indian Clinical Trials Market Analysis Report By Indication (Oncology, Autoimmune), By Phase (I/II/III/IV), By Study Design (Interventional, Observational), Vendor Landscape, And Segment Forecasts, 2018 - 2025” report has been added to ResearchAndMarkets.com’s offering.
The India clinical trials market size is expected to reach USD 3.15 billion by 2025. It is projected to register a CAGR of 8.7% over the forecast period.
Globalization of clinical trials, adoption of new technology in clinical research, growing disease variation and prevalence, and increasing R&D promoting outsourcing are the key factors driving the market.
India is a country of nearly 1.3 billion individuals with varying genetic background and thus offers a large treatment-nave patient pool for development of therapeutics on a range of disease conditions. Furthermore, the economic, environmental, and ecological variations in the 29 states and seven union territories in the country present the most diverse disease profiles. For instance, Rajasthan, Bihar, Jharkhand, and Uttar Pradesh have less dominance of non-communicable diseases as compared to Kerala, Tamil Nadu, and Goa.
Despite this, Indian clinical trials market faced a lag phase from 2013 to 2015. This can be attributed to regulatory uncertainties. This has promoted streamlining of the regulations and has led to increasing harmonization and reduction in approval time, thus making India a favorable destination for clinical trials. Furthermore, the cost of carrying out clinical trials in India is nearly 40-70% less than that in Europe or U.S. Thus, the cost efficiency, along with availability of skilled professionals, and ease of doing business, is anticipated to fuel the market growth.
The increasing R&D investments by pharmaceutical and biopharmaceutical companies have led to increased demand for Contract research Organizations (CROs) and outsourcing of trials to curb the cost. Furthermore, outsourcing enables drug companies to focus on their core competencies and aids in improving their productivity.
Further key findings from the report suggest:
- Phase I trials are projected to witness a remarkable CAGR of 10.5% over forecast period, attributed to increasing R&D spending by pharmaceutical and biopharmaceutical companies.
- Interventional study design led the market Indian clinical trials market in 2017 owing to the greater accuracy offered by them as compared to observational study design.
- Oncology led the indication segment in terms of market share in 2017 due to high prevalence of cancer and the consequent rise in demand for innovative therapies.
- Some of the key companies present in the market are IQVIA, Inc.; ICON PLC; PRA Health Sciences; GVK Biosciences; PAREXEL International Corporation; and Syngene International Ltd.
Chapter 1 Report Scope
1.1 Estimates and Forecast Timeline
Chapter 2 Methodology
2.1 Research Methodology
2.1.1 Information procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
2.4 Region Share Calculation
2.5 List of Secondary Sources
2.6 List of Primary Sources
2.7 List of Abbreviations
Chapter 3 Executive Summary
3.1 Market Snapshot
Chapter 4 Industry Outlook
4.1 Market Segmentation
4.2 Business Segment Trends
4.3 Market Variable Analysis
4.3.1 Market driver analysis
126.96.36.199 Globalization of clinical trials
188.8.131.52 Adoption of new technology in clinical research
184.108.40.206 Growing disease variation and prevalence
220.127.116.11 Increasing research and development promoting outsourcing
4.3.2 Market restraint analysis
18.104.22.168 Pricing pressure
22.214.171.124 Regulatory issues.
4.4 Penetration & Growth Prospect Mapping
4.5 Business Environment Analysis tools
4.5.1 SWOT Analysis, by PEST
4.5.2 Porter’s five forces analysis
4.5.3 Clinical trial registry.
4.5.4 The objective of the registry
4.5.5 Future prospects
4.5.6 Clinical trial registration process flow.
Chapter 5 Phase Estimates And Trend Analysis
5.1 Indian Clinical Trials Market: Phase Movement Analysis
5.2 Phase I
5.3 Phase II
5.4 Phase III
5.5 Phase IV
Chapter 6 Study Design Estimates And Trend Analysis
6.1 Indian Clinical Trials Market: Study Design Movement Analysis
6.2 Interventional trials
6.3 Observational trials
6.4 Expanded access trials
Chapter 7 Indication Estimates And Trend Analysis
7.1 Indian Clinical Trials Market: Indication Movement Analysis
7.3 Pain management
7.5 CNS Conditions
Chapter 8 Company Profiles
8.1 Strategic Framework
8.2 Company Profiles
8.2.1 IQVIA Holdings Inc. (QUintilesIMS)
8.2.2 Paraxel International Corporation
8.2.3 Pharmaceutical Product Development LLC
8.2.4 Charles River Laboratory
8.2.5 Icon PLC
8.2.6 PRA Health Sciences Inc.
8.2.7 Chiltern International Ltd. (Covance Inc.)
8.2.8 Syneos Health Inc. (Inc Research)
8.2.9 SGS S.A.
8.2.10 Syngene International Limited
8.2.11 Aurigene Discovery Technologies Limited
8.2.12 GVK Biosciences PVT. Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/tqk57d/indian_clinical?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190313005412/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Clinical Trials
KEYWORD: ASIA PACIFIC INDIA
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 03/13/2019 08:35 AM/DISC: 03/13/2019 08:35 AM